argenex SE $ARGX Shares Purchased by Millennium Management LLC

Millennium Management LLC raised its stake in argenex SE (NASDAQ:ARGX) by 316.9% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 268,604 shares of the company’s stock after purchasing an additional 204,180 shares during the quarter. Millennium Management LLC owned about 0.44% of argenex worth $158,977,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the stock. Eventide Asset Management LLC boosted its holdings in shares of argenex by 9.2% in the 1st quarter. Eventide Asset Management LLC now owns 113,743 shares of the company’s stock valued at $67,319,000 after purchasing an additional 9,599 shares during the last quarter. Checkpoint Capital L.P. boosted its holdings in shares of argenex by 24.3% in the 1st quarter. Checkpoint Capital L.P. now owns 115,000 shares of the company’s stock valued at $68,064,000 after purchasing an additional 22,500 shares during the last quarter. Banque Transatlantique SA acquired a new position in shares of argenex in the 1st quarter valued at $62,000. AQR Capital Management LLC boosted its holdings in shares of argenex by 32.1% in the 1st quarter. AQR Capital Management LLC now owns 502 shares of the company’s stock valued at $297,000 after purchasing an additional 122 shares during the last quarter. Finally, Advisors Asset Management Inc. boosted its holdings in shares of argenex by 6.2% in the 1st quarter. Advisors Asset Management Inc. now owns 1,201 shares of the company’s stock valued at $711,000 after purchasing an additional 70 shares during the last quarter. Institutional investors and hedge funds own 60.32% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. Guggenheim lifted their price target on shares of argenex from $1,060.00 to $1,070.00 and gave the company a “buy” rating in a report on Friday, August 1st. Deutsche Bank Aktiengesellschaft raised shares of argenex from a “hold” rating to a “buy” rating in a research note on Tuesday, July 8th. Bank of America raised their target price on shares of argenex from $880.00 to $887.00 and gave the company a “buy” rating in a research note on Tuesday. Robert W. Baird raised shares of argenex from a “neutral” rating to an “outperform” rating and set a $680.00 target price on the stock in a research note on Tuesday, May 13th. Finally, Piper Sandler raised their target price on shares of argenex from $750.00 to $820.00 and gave the company an “overweight” rating in a research note on Tuesday, August 26th. Two analysts have rated the stock with a Strong Buy rating and twenty-one have issued a Buy rating to the company. According to data from MarketBeat, argenex has a consensus rating of “Buy” and a consensus target price of $772.84.

argenex Price Performance

argenex stock opened at $733.66 on Friday. argenex SE has a 12-month low of $510.05 and a 12-month high of $742.52. The company has a market capitalization of $44.90 billion, a price-to-earnings ratio of 37.62, a price-to-earnings-growth ratio of 0.76 and a beta of 0.41. The firm’s fifty day moving average price is $624.07 and its 200 day moving average price is $601.86.

argenex (NASDAQ:ARGX) last released its quarterly earnings results on Thursday, July 31st. The company reported $3.74 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.84 by $0.90. argenex had a net margin of 40.98% and a return on equity of 21.06%. The firm had revenue of $866.79 million for the quarter, compared to the consensus estimate of $776.82 million. Analysts forecast that argenex SE will post 3.13 earnings per share for the current fiscal year.

argenex Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.